TY  - EJOU
AU  - YANG, HONG 
AU  - LI, WAN 
AU  - REN, LIWEN 
AU  - YANG, YIHUI 
AU  - ZHANG, YIZHI 
AU  - GE, BINBIN 
AU  - LI, SHA 
AU  - ZHENG, XIANGJIN 
AU  - LIU, JINYI 
AU  - ZHANG, SEN 
AU  - DU, GUANHUA 
AU  - TANG, BO 
AU  - WANG, HONGQUAN 
AU  - WANG, JINHUA 

TI  - Progress on diagnostic and prognostic markers of pancreatic cancer
T2  - Oncology Research

PY  - 2023
VL  - 31
IS  - 2
SN  - 1555-3906

AB  - Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate, whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed. Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens. So far, CA19-9 is the only biomarker for pancreatic cancer approved by the FDA, but its effectiveness is limited by low sensitivity and specificity. With recent advances in genomics, proteomics, metabolomics, and other analytical and sequencing technologies, the rapid acquisition and screening of biomarkers is now possible. Liquid biopsy also occupies a significant place due to its unique advantages. In this review, we systematically describe and evaluate the available biomarkers that have the greatest potential as vital tools in diagnosing and treating pancreatic cancer.
KW  - Pancreatic cancer; Biomarkers; Liquid biopsy; Systematic review

DO  - 10.32604/or.2023.028905